Walvax Biotechnology (300142.SZ): Lyophilized herpes zoster virus mRNA vaccine initiates Phase I clinical trial

Walvax Biotechnology (300142.SZ) announced that the lyophilized herpes zoster virus mRNA vaccine, jointly developed by its subsidiaries Beijing Walvax Innovation Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Technology Co., Ltd., together with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. (referred to as "Blue Magpie Biopharmaceutical"), has completed preparations for the Phase I clinical trial. A Phase I clinical trial kick-off meeting was held today, officially launching the Phase I clinical trial. The initiation of the Phase I clinical trial for this vaccine represents a milestone progress in the vaccine's R&D process. The company will actively advance the clinical research of the vaccine. If the vaccine is successfully developed, it will further enrich the company's product portfolio in the mRNA vaccine field and the adult vaccine field, laying a solid foundation for the company's long-term, sustainable, and steady development.